Eris Lifesciences Ltd · NSE:ERIS

Eris Lifesciences — Merger or Acquisition (March 2024)

15 slides from Eris Lifesciences's merger presentation, Mar 14, 2024

  1. Slide 1: Cover letter to stock exchanges

    Date: 14 March 2024 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the requirem

  2. Slide 2: Eris Proposes to Acquire India Branded Formulations business of Biocon Biologics

    Eris Proposes to Acquire India Branded Formulations business of Biocon Biologics and 19% stake in Swiss Parenterals Presentation 14th March 2024

  3. Slide 3: Acquisition of Biocon Business – Two Key Strategic Objectives

    ACQUISITION OF BIOCON BUSINESS – TWO KEY STRATEGIC OBJECTIVES Eris proposes to acquire (1) Jumpstarting India Branded Sterile Injectable Leverage BIOCON’s Business - Entry into synergies with Indian Branded Critical Care and Oncology Swiss Formulations business Parenterals for (2) Leadership in Insu

  4. Slide 4: Swiss Parenterals + Biocon – Sharing the Big Picture Now

    SWISS PARENTERALS + BIOCON – SHARING THE BIG PICTURE NOW Swiss Parenterals – Feb ‘24 Biocon India Branded Business – Mar ‘24 • Dossier driven sterile injectable • Branded injectable business with business in RoW Markets revenue INR. 360+ cr p.a. and an • Product range – 190+ unique attractive produc

  5. Slide 5: Swiss Parenterals + Biocon Deals – What We Expect to Make of Them

    SWISS PARENTERALS + BIOCON DEALS – WHAT WE EXPECT TO MAKE OF THEM • Biocon business with revenue base of Rs. 360+ crore - ideal launch platform to address the India injectables market • Quick scale up of Biocon revenue base with new product launches from Swiss Targeting our next Parenterals’ current

  6. Slide 6: Eris Journey in the Insulin Business

    ERIS JOURNEY IN THE INSULIN BUSINESS • Eris entered the India Insulin market in Jan 2022 with the formation of a 70:30 Joint Venture with MJ Biopharm Ltd. • Commercialised two products Xsulin (Recombinant Human Insulin) and Xglar (Glargine) • Achieved quick scale-up of a greenfield business • FY23 –

  7. Slide 7: Biocon's Insulin Portfolio Will Leapfrog Us to a Leadership Position

    BIOCON’S INSULIN PORTFOLIO WILL LEAPFROG US TO A LEADERSHIP POSITION • Largest Indian brand of Glargine in the market • The only Glargine biosimilar with clinical data on complete interchangeability with the • Combined innovator product Lantus revenue of ~ INR • Expansion in market share (volume) fr

  8. Slide 8: Biocon's Critical Care Portfolio and Synergies with Swiss Parenterals

    BIOCON’S CRITICAL CARE PORTFOLIO AND SYNERGIES WITH SWISS PARENTERALS Leading Brands Business Highlights and Synergies with SPL • Revenue base of INR 80 cr. p.a. with leading brands in Immunoglobulins, Human Albumin, Enoxaparin, Heparin, Piperacillin+Tazobactum and Meropenem • Comprehensive hospital

  9. Slide 9: Oncology – The Biocon Business Brings Us Three Significant MABs

    ONCOLOGY – THE BIOCON BUSINESS BRINGS US THREE SIGNIFICANT MABs ▪ Nimotuzumab - India’s first novel MAB for head and neck cancer ▪ Potential additional cancer indications (approved in other world markets) – Pancreatic, Nasopharyngeal, Esophagal, Glioma • Revenue of ~ INR 80 crore p.a. ▪ First biosim

  10. Slide 10: The Deal Is in Line with the Salient Features of Our M&A Strategy

    THE DEAL IS IN LINE WITH THE SALIENT FEATURES OF OUR M&A STRATEGY… • Expand our presence in existing therapies and/ or Enter New Therapies • Turn around fundamentally good businesses that are sub-optimally run • Target quick value creation – turnaround in 12-18 months from acquisition • “Owner Manag

  11. Slide 11: …Which Have Delivered Tangible Impact Over the Years

    …WHICH HAVE DELIVERED TANGIBLE IMPACT OVER THE YEARS Year Target Deal Rationale Business Impact • Strides India Branded • Scale-up of VMN franchise (Renerve) • 2.5x growth in 2017 Renerve Formulations Business • Entry into CNS therapy • 4x scale up in CNS 2019 • Zomelis brand from Novartis • Entry i

  12. Slide 12: Biocon India Branded Formulations Business – Deal Contours

    BIOCON INDIA BRANDED FORMULATIONS BUSINESS – DEAL CONTOURS ▪ Eris has signed a definitive agreement to acquire the Indian Branded Formulations business of Biocon Biologics Ltd. ▪ The scope of the acquisition includes the following aspects as a going concern: ▪ The entire Indian Branded Formulations

  13. Slide 13: Streamlining Corporate Structure and Rebuilding Balance Sheet Strength

    STREAMLINING CORPORATE STRUCTURE AND REBUILDING BALANCE SHEET STRENGTH • Eris Lifesciences to acquire additional 19% stake in Swiss Parenterals from Eris Promoter group – a temporary/ bridge arrangement to be reversed • Committed to deleverage balance sheet • Sustained strong cashflow (avg OCF = 75%

  14. Slide 14: All Building Blocks Are Now in Place for INR 5000 Crore Revenue

    ALL BUILDING BLOCKS ARE NOW IN PLACE FOR INR 5000 CRORE REVENUE Growth Engines added - May 2022 – Mar 2024 1. Injectable Anti-Diabetes (Insulins, GLP-1) Strategic Objectives FY25-FY28 2. Dermatology • Integration of/ Value Creation 3. Platform for Indian Sterile Injectables market from FY24 deals 4.

  15. Slide 15: Thank You

    Eris ERIS LIFESCIENCES LIMITED THANK YOU

Eris Lifesciences — Merger or Acquisition (March 2024) on 6ix